etodolac has been researched along with Aberrant Crypt Foci in 1 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Aberrant Crypt Foci: Clusters of colonic crypts that appear different from the surrounding mucosa when visualized after staining. They are of interest as putative precursors to colorectal adenomas and potential biomarkers for colorectal carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 9.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 5.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takayama, T | 1 |
| Nagashima, H | 1 |
| Maeda, M | 1 |
| Nojiri, S | 1 |
| Hirayama, M | 1 |
| Nakano, Y | 1 |
| Takahashi, Y | 1 |
| Sato, Y | 1 |
| Sekikawa, H | 1 |
| Mori, M | 1 |
| Sonoda, T | 1 |
| Kimura, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
1 trial available for etodolac and Aberrant Crypt Foci
| Article | Year |
|---|---|
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2011 |